Literature DB >> 312747

The identification of urogastrone in serum, saliva, and gastric juice.

H Gregory, S Walsh, C R Hopkins.   

Abstract

Urogastrone, a peptide isolated from human urine, is known to cause inhibition of gastric acid secretion and proliferation of fibroblasts in culture; furthermore immunofluorescent localization techniques show it to be present in submandibular and Brunner's glands. Serum, saliva, and gastric juice samples have now been fractionated upon Sephadex G-200 and G-50 and the immunoreactive urogastrone located using a specific radioimmunoassay. Biologic activity was shown by mitogenic studies with 3T6 fibroblasts. In serum, the major immunoreactive component was ca. 1-2 X 10(5) daltons, but trypsin treatment then gave a smaller biologically active species in the same position as pure urogastrone on Sephadex G-50. Both saliva and gastric juice showed major components at the position defined by urogastrone, and these also stimulated the uptake of [H]thymidine into the fibroblasts. It is concluded that a urogastrone-like molecule can be released enzymically from a high molecular weight serum precursor and that the small biologically active peptide is also a normal component of saliva and gastric juice.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 312747

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

1.  Epidermal growth factor-urogastrone causes vasodilatation in the anesthetized dog.

Authors:  B S Gan; K L MacCannell; M D Hollenberg
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

Review 2.  Role of epidermal growth factor in peptic ulcer healing.

Authors:  A Calabrò; S Milani; I Paladini; B Orsini; G Salvadori; C Surrenti
Journal:  Dig Dis Sci       Date:  1995-11       Impact factor: 3.199

3.  Localization of epidermal growth factor/transforming growth factor-alpha receptor in the human gastric mucosa. An immunohistochemical and in situ hybridization study.

Authors:  B Orsini; A Calabrò; S Milani; C Grappone; H Herbst; C Surrenti
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

4.  Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis.

Authors:  D Birk; F Gansauge; S Gansauge; A Formentini; A Lucht; H G Beger
Journal:  Int J Pancreatol       Date:  1999-04

5.  Inhibition of acid formation by epidermal growth factor in the isolated rabbit gastric glands.

Authors:  A Dembiński; D Drozdowicz; H Gregory; S J Konturek; Z Warzecha
Journal:  J Physiol       Date:  1986-09       Impact factor: 5.182

6.  Ménétrier's disease. A trivalent gastropathy.

Authors:  T M Sundt; C C Compton; R A Malt
Journal:  Ann Surg       Date:  1988-12       Impact factor: 12.969

7.  Immunohistochemical localization of epidermal growth factor in rat and man.

Authors:  S S Poulsen; E Nexø; P S Olsen; J Hess; P Kirkegaard
Journal:  Histochemistry       Date:  1986

8.  Secretion of protein and epidermal growth factor (EGF) by transplanted human pancreas.

Authors:  J W Konturek; M Buesing; U T Hopt; J Stachura; H D Becker; S J Konturek
Journal:  Int J Pancreatol       Date:  1992-08

9.  Immunohistochemical localization of epidermal growth factor in the second-trimester human fetus.

Authors:  S S Poulsen; N Kryger-Baggesen; E Nexø
Journal:  Histochem Cell Biol       Date:  1996-02       Impact factor: 4.304

10.  Development and validation of two solid-phase enzyme immunoassays (ELISA) for quantitation of human epidermal growth factors (hEGFs).

Authors:  N Sizemore; R C Dudeck; C M Barksdale; G D Nordblom; W T Mueller; P McConnell; D S Wright; A Guglietta; B S Kuo
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.